Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to ceftazidime–avibactam and underlying mechanisms

18 Dec 2019

Abstract excerpt

OBJECTIVE: Ceftazidime-avibactam (CAZ-AVI) is a novel synthetic β-lactamase inhibitor combination. Although the combination has been available clinically for only a few years, cases of resistance to CAZ-AVI have already been reported. METHODS: In the present review, we summarize the distribution of CAZ-AVI-resistant strains and the possible resistance mechanisms. RESULTS: There are no significant differences in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Antibiotics Pharmacokinetics and Efficacy
Share to Infections and bacterial resistance

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31863899
DOI: 10.1016/j.jgar.2019.12.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to ceftazidime–avibactam and underlying mechanismsPMID 31863899Read ↗

Epidemiology and Mechanisms of Ceftazidime–Avibactam Resistance in Gram-Negative BacteriaSemantic proximity Read ↗

Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactamSemantic proximity Read ↗

Resistance to ceftazidime–avibactam and other new β-lactams in Pseudomonas aeruginosa clinical isolates: a multi-center surveillance studySemantic proximity Read ↗

Molecular Epidemiology of Infections Caused by Carbapenem-Resistant <em>Pseudomonas aeruginosa</em> and Enterobacterales and Susceptibility of Isolates to Ceftazidime-AvibactamSemantic proximity Read ↗

Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American HospitalsSemantic proximity Read ↗

Susceptibility of Ceftazidime-avibactam in bloodstream infections caused by multidrug-resistant Enterobacterales and Pseudomonas aeruginosaSemantic proximity Read ↗

Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015–16Semantic proximity Read ↗

Ceftazidime-avibactamSemantic proximity Read ↗

Aztreonam-avibactam: an option against carbapenem-resistant Enterobacterales with emerging resistanceSemantic proximity Read ↗

Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from SwitzerlandSemantic proximity Read ↗

Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates from United States Medical Centers in 2016-2018.Semantic proximity Read ↗

Avibactam and Class C β-Lactamases: Mechanism of Inhibition, Conservation of the Binding Pocket, and Implications for ResistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.